| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mucocutaneous Lymph Node Syndrome | 30 | 2019 | 546 | 2.110 |
Why?
|
| Nitric Oxide Synthase | 16 | 2004 | 916 | 1.220 |
Why?
|
| Chest Pain | 6 | 2017 | 1114 | 1.180 |
Why?
|
| Coronary Aneurysm | 10 | 2019 | 237 | 0.900 |
Why?
|
| Management Audit | 1 | 2017 | 23 | 0.620 |
Why?
|
| Nitric Oxide | 14 | 2007 | 2132 | 0.600 |
Why?
|
| Echocardiography | 21 | 2018 | 5102 | 0.580 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 1 | 2017 | 153 | 0.560 |
Why?
|
| Pediatrics | 6 | 2017 | 3475 | 0.530 |
Why?
|
| Cardiology Service, Hospital | 4 | 2011 | 246 | 0.470 |
Why?
|
| Patient Care Management | 3 | 2011 | 306 | 0.460 |
Why?
|
| Health Resources | 2 | 2017 | 911 | 0.450 |
Why?
|
| Cardiology | 4 | 2017 | 1668 | 0.440 |
Why?
|
| Heart Diseases | 9 | 2016 | 2788 | 0.430 |
Why?
|
| Coronary Vessels | 8 | 2018 | 3107 | 0.430 |
Why?
|
| Immunoglobulins, Intravenous | 11 | 2016 | 652 | 0.430 |
Why?
|
| Golgi Apparatus | 3 | 2004 | 410 | 0.410 |
Why?
|
| Electrocardiography | 12 | 2017 | 6442 | 0.400 |
Why?
|
| Needs Assessment | 1 | 2017 | 1147 | 0.390 |
Why?
|
| Nitric Oxide Synthase Type III | 17 | 2007 | 689 | 0.380 |
Why?
|
| Program Evaluation | 3 | 2017 | 2488 | 0.360 |
Why?
|
| Serine | 6 | 2004 | 826 | 0.360 |
Why?
|
| Standard of Care | 1 | 2011 | 564 | 0.300 |
Why?
|
| Calmodulin | 3 | 2004 | 209 | 0.300 |
Why?
|
| Caveolins | 3 | 2003 | 104 | 0.280 |
Why?
|
| Delivery of Health Care, Integrated | 2 | 2011 | 941 | 0.280 |
Why?
|
| Endothelium, Vascular | 12 | 2004 | 4456 | 0.270 |
Why?
|
| Referral and Consultation | 2 | 2017 | 3528 | 0.250 |
Why?
|
| Critical Pathways | 3 | 2016 | 476 | 0.240 |
Why?
|
| Proto-Oncogene Proteins | 10 | 2004 | 4554 | 0.240 |
Why?
|
| Heart Defects, Congenital | 11 | 2015 | 4584 | 0.240 |
Why?
|
| Coronary Artery Bypass | 3 | 2016 | 2289 | 0.230 |
Why?
|
| Ductus Arteriosus, Patent | 2 | 1997 | 209 | 0.230 |
Why?
|
| Quality Improvement | 2 | 2017 | 3749 | 0.230 |
Why?
|
| Practice Guidelines as Topic | 6 | 2017 | 7279 | 0.230 |
Why?
|
| Coronary Stenosis | 1 | 2010 | 834 | 0.230 |
Why?
|
| Child | 53 | 2020 | 77709 | 0.220 |
Why?
|
| Hydroxymethyl and Formyl Transferases | 1 | 2022 | 17 | 0.220 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2010 | 1873 | 0.210 |
Why?
|
| HSP90 Heat-Shock Proteins | 5 | 2007 | 434 | 0.200 |
Why?
|
| Child, Preschool | 43 | 2020 | 41006 | 0.200 |
Why?
|
| Disease Management | 4 | 2017 | 2459 | 0.200 |
Why?
|
| Exercise Test | 10 | 2017 | 2074 | 0.200 |
Why?
|
| Vasodilation | 3 | 2002 | 944 | 0.190 |
Why?
|
| Calcium | 3 | 2004 | 5756 | 0.190 |
Why?
|
| Infant | 44 | 2020 | 35136 | 0.190 |
Why?
|
| Munchausen Syndrome by Proxy | 1 | 2000 | 18 | 0.190 |
Why?
|
| Algorithms | 4 | 2017 | 13881 | 0.190 |
Why?
|
| Guideline Adherence | 4 | 2017 | 2266 | 0.190 |
Why?
|
| Coronary Angiography | 3 | 2010 | 4577 | 0.180 |
Why?
|
| Retroviridae Proteins, Oncogenic | 1 | 1999 | 76 | 0.170 |
Why?
|
| Cytoplasm | 1 | 2004 | 1539 | 0.170 |
Why?
|
| Atrioventricular Block | 1 | 2020 | 120 | 0.170 |
Why?
|
| Adolescent | 33 | 2020 | 85781 | 0.170 |
Why?
|
| Anti-Inflammatory Agents | 3 | 2016 | 1790 | 0.160 |
Why?
|
| Cell Membrane | 4 | 2004 | 3748 | 0.160 |
Why?
|
| Bradykinin | 1 | 1998 | 214 | 0.160 |
Why?
|
| Arachidonic Acids | 1 | 1998 | 299 | 0.160 |
Why?
|
| Health Personnel | 1 | 2011 | 3218 | 0.160 |
Why?
|
| Phosphorylation | 15 | 2004 | 8436 | 0.160 |
Why?
|
| Tetralogy of Fallot | 3 | 1998 | 623 | 0.150 |
Why?
|
| Heart Septal Defects, Atrial | 3 | 1997 | 478 | 0.150 |
Why?
|
| Attitude of Health Personnel | 1 | 2011 | 3843 | 0.150 |
Why?
|
| Hospitals, Pediatric | 6 | 2012 | 1775 | 0.150 |
Why?
|
| Ambulatory Care | 4 | 2017 | 2708 | 0.150 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2011 | 3923 | 0.140 |
Why?
|
| Decision Support Techniques | 2 | 2017 | 1956 | 0.140 |
Why?
|
| Death, Sudden | 1 | 1997 | 302 | 0.130 |
Why?
|
| Regional Health Planning | 1 | 2016 | 97 | 0.130 |
Why?
|
| Ventricular Function | 2 | 1994 | 416 | 0.130 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2020 | 612 | 0.130 |
Why?
|
| Male | 56 | 2020 | 350118 | 0.130 |
Why?
|
| Cardiovascular Diseases | 4 | 2017 | 15165 | 0.130 |
Why?
|
| Immunologic Factors | 2 | 2016 | 1580 | 0.120 |
Why?
|
| Cattle | 11 | 2007 | 3922 | 0.120 |
Why?
|
| Cardiac Imaging Techniques | 1 | 2016 | 269 | 0.110 |
Why?
|
| Humans | 92 | 2022 | 744343 | 0.110 |
Why?
|
| Heart Septum | 1 | 1994 | 313 | 0.110 |
Why?
|
| COS Cells | 4 | 2004 | 1161 | 0.110 |
Why?
|
| Stents | 2 | 1996 | 3280 | 0.110 |
Why?
|
| Heart Function Tests | 1 | 1993 | 330 | 0.110 |
Why?
|
| Syncope | 1 | 2016 | 429 | 0.110 |
Why?
|
| Female | 48 | 2020 | 380194 | 0.110 |
Why?
|
| Endothelial Growth Factors | 4 | 2002 | 694 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-akt | 11 | 2007 | 2503 | 0.100 |
Why?
|
| Infant, Newborn | 19 | 2020 | 25625 | 0.100 |
Why?
|
| Lymphokines | 4 | 2002 | 949 | 0.100 |
Why?
|
| Probability | 1 | 2017 | 2505 | 0.100 |
Why?
|
| Pulmonary Artery | 3 | 1997 | 1912 | 0.100 |
Why?
|
| Caveolin 1 | 3 | 2003 | 263 | 0.100 |
Why?
|
| Retrospective Studies | 15 | 2020 | 77449 | 0.100 |
Why?
|
| Pericarditis | 2 | 1990 | 128 | 0.090 |
Why?
|
| Superantigens | 3 | 1995 | 129 | 0.090 |
Why?
|
| Advisory Committees | 1 | 2015 | 775 | 0.090 |
Why?
|
| Program Development | 3 | 2011 | 1316 | 0.090 |
Why?
|
| Young Adult | 12 | 2020 | 56430 | 0.090 |
Why?
|
| Social Class | 1 | 2019 | 1999 | 0.090 |
Why?
|
| Haemophilus Infections | 1 | 1990 | 95 | 0.090 |
Why?
|
| Follow-Up Studies | 13 | 2020 | 39050 | 0.090 |
Why?
|
| Radiography, Thoracic | 2 | 2013 | 1265 | 0.090 |
Why?
|
| Vascular Endothelial Growth Factor A | 6 | 2007 | 3508 | 0.080 |
Why?
|
| 6-Ketoprostaglandin F1 alpha | 1 | 1988 | 83 | 0.080 |
Why?
|
| Length of Stay | 3 | 2019 | 6309 | 0.080 |
Why?
|
| Warfarin | 1 | 2017 | 1496 | 0.080 |
Why?
|
| Prostaglandins E | 1 | 1988 | 172 | 0.080 |
Why?
|
| Nurse Practitioners | 1 | 2012 | 270 | 0.080 |
Why?
|
| Thromboxane B2 | 1 | 1988 | 152 | 0.080 |
Why?
|
| Parents | 1 | 2002 | 3407 | 0.080 |
Why?
|
| Boston | 5 | 2013 | 9313 | 0.080 |
Why?
|
| Evaluation Studies as Topic | 4 | 1994 | 1681 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factors | 4 | 2002 | 772 | 0.080 |
Why?
|
| Appointments and Schedules | 1 | 2012 | 417 | 0.080 |
Why?
|
| Pericardial Effusion | 1 | 1990 | 247 | 0.080 |
Why?
|
| Anxiety | 1 | 2002 | 4297 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 4 | 2010 | 9274 | 0.080 |
Why?
|
| Health Status Disparities | 1 | 2019 | 1797 | 0.080 |
Why?
|
| Embolization, Therapeutic | 1 | 1997 | 1392 | 0.080 |
Why?
|
| Diastole | 1 | 2009 | 791 | 0.070 |
Why?
|
| Fellowships and Scholarships | 1 | 2015 | 1076 | 0.070 |
Why?
|
| Atherosclerosis | 1 | 2022 | 3445 | 0.070 |
Why?
|
| Umbilical Veins | 2 | 2004 | 433 | 0.070 |
Why?
|
| Animals | 28 | 2022 | 168757 | 0.070 |
Why?
|
| Comprehension | 1 | 2011 | 610 | 0.070 |
Why?
|
| Fever | 2 | 2013 | 1616 | 0.070 |
Why?
|
| Transposition of Great Vessels | 1 | 2010 | 588 | 0.070 |
Why?
|
| Transfection | 3 | 2004 | 5892 | 0.070 |
Why?
|
| Enzyme Activation | 5 | 2004 | 3701 | 0.060 |
Why?
|
| Cor Triatriatum | 2 | 1999 | 14 | 0.060 |
Why?
|
| Myristic Acids | 1 | 2004 | 48 | 0.060 |
Why?
|
| Prognosis | 8 | 2017 | 29063 | 0.060 |
Why?
|
| Palmitic Acids | 1 | 2004 | 54 | 0.060 |
Why?
|
| RNA, Messenger | 1 | 2000 | 13033 | 0.060 |
Why?
|
| Diagnosis, Differential | 2 | 2017 | 12959 | 0.060 |
Why?
|
| Vanadates | 1 | 2004 | 82 | 0.060 |
Why?
|
| Immunization, Passive | 3 | 1996 | 623 | 0.060 |
Why?
|
| Sensitivity and Specificity | 2 | 2017 | 14722 | 0.060 |
Why?
|
| Hospital Costs | 1 | 2010 | 985 | 0.060 |
Why?
|
| Age Factors | 4 | 2017 | 18370 | 0.060 |
Why?
|
| Cell Movement | 3 | 2007 | 5217 | 0.060 |
Why?
|
| Aspirin | 4 | 2004 | 3282 | 0.060 |
Why?
|
| Databases, Factual | 2 | 2017 | 7729 | 0.060 |
Why?
|
| Myelin Proteins | 1 | 2004 | 215 | 0.060 |
Why?
|
| Heart Murmurs | 2 | 2002 | 94 | 0.060 |
Why?
|
| Societies, Medical | 1 | 2015 | 3743 | 0.050 |
Why?
|
| Heart | 1 | 1996 | 4467 | 0.050 |
Why?
|
| Threonine | 1 | 2003 | 279 | 0.050 |
Why?
|
| Muscle, Smooth, Vascular | 3 | 2004 | 1504 | 0.050 |
Why?
|
| Tachycardia | 1 | 1985 | 619 | 0.050 |
Why?
|
| Constriction, Pathologic | 2 | 1996 | 1107 | 0.050 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2004 | 2282 | 0.050 |
Why?
|
| Evidence-Based Medicine | 2 | 2011 | 3610 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3133 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3240 | 0.050 |
Why?
|
| Heart Neoplasms | 1 | 2005 | 374 | 0.050 |
Why?
|
| Anticoagulants | 1 | 2017 | 4599 | 0.050 |
Why?
|
| Norovirus | 1 | 2002 | 35 | 0.050 |
Why?
|
| Baculoviridae | 1 | 2002 | 118 | 0.050 |
Why?
|
| Neointima | 1 | 2022 | 135 | 0.050 |
Why?
|
| Hospital Mortality | 1 | 1995 | 5317 | 0.050 |
Why?
|
| Methylprednisolone | 1 | 2003 | 387 | 0.050 |
Why?
|
| Adenoviridae | 5 | 2007 | 1099 | 0.050 |
Why?
|
| Lung | 3 | 2007 | 9856 | 0.050 |
Why?
|
| Coronary Vessel Anomalies | 1 | 2004 | 314 | 0.050 |
Why?
|
| Kinetics | 4 | 2003 | 6473 | 0.050 |
Why?
|
| Sex Factors | 2 | 2010 | 10397 | 0.050 |
Why?
|
| Respiratory Syncytial Virus Infections | 2 | 1996 | 329 | 0.050 |
Why?
|
| Infant, Premature, Diseases | 2 | 1999 | 706 | 0.050 |
Why?
|
| Risk Factors | 9 | 2020 | 72290 | 0.050 |
Why?
|
| Receptors, Growth Factor | 1 | 2001 | 334 | 0.050 |
Why?
|
| Pulmonary Valve | 2 | 1996 | 437 | 0.050 |
Why?
|
| Coronary Disease | 5 | 2000 | 6077 | 0.050 |
Why?
|
| Risk Assessment | 3 | 2017 | 23338 | 0.050 |
Why?
|
| Infant, Premature | 3 | 2000 | 2044 | 0.050 |
Why?
|
| Dilatation, Pathologic | 2 | 2013 | 520 | 0.050 |
Why?
|
| gamma-Globulins | 2 | 1991 | 124 | 0.050 |
Why?
|
| Hemangioma | 1 | 2005 | 738 | 0.050 |
Why?
|
| Hypertension, Portal | 1 | 2002 | 220 | 0.040 |
Why?
|
| Piperidines | 2 | 1998 | 1602 | 0.040 |
Why?
|
| DNA, Complementary | 2 | 2002 | 2050 | 0.040 |
Why?
|
| Delivery of Health Care | 2 | 2016 | 5319 | 0.040 |
Why?
|
| Protein Structure, Tertiary | 2 | 2004 | 3846 | 0.040 |
Why?
|
| Heart Septal Defects, Ventricular | 2 | 1997 | 488 | 0.040 |
Why?
|
| Arginine | 1 | 2003 | 944 | 0.040 |
Why?
|
| DNA Fragmentation | 1 | 2000 | 242 | 0.040 |
Why?
|
| Medical History Taking | 2 | 2016 | 783 | 0.040 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2010 | 3537 | 0.040 |
Why?
|
| Cysteine | 1 | 2004 | 874 | 0.040 |
Why?
|
| Exercise Therapy | 1 | 2006 | 906 | 0.040 |
Why?
|
| Carotid Artery, Common | 1 | 2000 | 183 | 0.040 |
Why?
|
| Oncogene Protein v-akt | 1 | 1999 | 135 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2012 | 3396 | 0.040 |
Why?
|
| Capsid | 1 | 2002 | 436 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 19905 | 0.040 |
Why?
|
| Purines | 1 | 2022 | 594 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2010 | 4420 | 0.040 |
Why?
|
| Blotting, Western | 2 | 2004 | 5179 | 0.040 |
Why?
|
| Apnea | 1 | 2000 | 195 | 0.040 |
Why?
|
| Bacterial Toxins | 2 | 1995 | 931 | 0.040 |
Why?
|
| Polyunsaturated Alkamides | 1 | 1998 | 29 | 0.040 |
Why?
|
| Tachycardia, Ectopic Junctional | 1 | 1998 | 19 | 0.040 |
Why?
|
| Capsid Proteins | 1 | 2002 | 479 | 0.040 |
Why?
|
| Severity of Illness Index | 3 | 2016 | 15540 | 0.040 |
Why?
|
| Predictive Value of Tests | 4 | 2017 | 15076 | 0.040 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2001 | 664 | 0.040 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2022 | 687 | 0.040 |
Why?
|
| Catheter Ablation | 2 | 2004 | 2758 | 0.040 |
Why?
|
| Potassium Channel Blockers | 1 | 1998 | 171 | 0.040 |
Why?
|
| Cell Line | 5 | 2004 | 15997 | 0.040 |
Why?
|
| Body Surface Area | 2 | 2013 | 198 | 0.040 |
Why?
|
| Simvastatin | 1 | 2000 | 360 | 0.040 |
Why?
|
| Cloning, Molecular | 2 | 2002 | 4320 | 0.040 |
Why?
|
| Endocannabinoids | 1 | 1998 | 116 | 0.040 |
Why?
|
| Biological Factors | 1 | 1998 | 164 | 0.040 |
Why?
|
| Physical Examination | 2 | 2016 | 1237 | 0.040 |
Why?
|
| Pulmonary Valve Stenosis | 1 | 1998 | 183 | 0.040 |
Why?
|
| Adult | 12 | 2015 | 214055 | 0.040 |
Why?
|
| Arachidonic Acid | 1 | 1998 | 434 | 0.040 |
Why?
|
| Equipment Design | 3 | 1994 | 3582 | 0.040 |
Why?
|
| Dogs | 2 | 2000 | 3912 | 0.040 |
Why?
|
| Microscopy, Fluorescence | 1 | 2004 | 2699 | 0.040 |
Why?
|
| Cells, Cultured | 8 | 2007 | 19229 | 0.040 |
Why?
|
| Staphylococcus aureus | 2 | 1995 | 1451 | 0.030 |
Why?
|
| United States | 5 | 2017 | 69872 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2001 | 1285 | 0.030 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 1998 | 419 | 0.030 |
Why?
|
| Remission, Spontaneous | 1 | 2016 | 382 | 0.030 |
Why?
|
| von Willebrand Factor | 1 | 2000 | 669 | 0.030 |
Why?
|
| Matched-Pair Analysis | 1 | 1996 | 288 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2016 | 12245 | 0.030 |
Why?
|
| Respiratory Syncytial Viruses | 2 | 1993 | 165 | 0.030 |
Why?
|
| Oxygen Consumption | 2 | 2006 | 1869 | 0.030 |
Why?
|
| Time Factors | 8 | 2016 | 40075 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2000 | 1850 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2004 | 1855 | 0.030 |
Why?
|
| International Normalized Ratio | 1 | 2017 | 367 | 0.030 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 1996 | 264 | 0.030 |
Why?
|
| Aortic Diseases | 1 | 2001 | 742 | 0.030 |
Why?
|
| Molecular Sequence Data | 4 | 2003 | 18111 | 0.030 |
Why?
|
| Quality of Health Care | 1 | 2010 | 4371 | 0.030 |
Why?
|
| Endothelial Cells | 1 | 2007 | 3479 | 0.030 |
Why?
|
| Ultrasonography | 3 | 2013 | 5985 | 0.030 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2000 | 1086 | 0.030 |
Why?
|
| Internship and Residency | 1 | 2015 | 5788 | 0.030 |
Why?
|
| Rats, Wistar | 1 | 1998 | 1901 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2012 | 5137 | 0.030 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 1996 | 139 | 0.030 |
Why?
|
| Rats | 3 | 2002 | 24260 | 0.030 |
Why?
|
| Phonocardiography | 1 | 1993 | 34 | 0.030 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 1994 | 177 | 0.030 |
Why?
|
| Infusions, Intravenous | 4 | 1998 | 2274 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2001 | 2938 | 0.030 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2001 | 1660 | 0.030 |
Why?
|
| Respirovirus Infections | 1 | 1993 | 50 | 0.030 |
Why?
|
| Swine | 2 | 1994 | 5917 | 0.030 |
Why?
|
| Attitude to Health | 1 | 2003 | 2052 | 0.030 |
Why?
|
| Long QT Syndrome | 1 | 1998 | 453 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2001 | 3002 | 0.030 |
Why?
|
| North America | 1 | 2017 | 1249 | 0.030 |
Why?
|
| Health Status | 2 | 2006 | 4034 | 0.030 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2001 | 1990 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2003 | 2564 | 0.030 |
Why?
|
| Signal Transduction | 6 | 2007 | 23403 | 0.030 |
Why?
|
| Competency-Based Education | 1 | 2015 | 211 | 0.030 |
Why?
|
| Hypertrophy, Right Ventricular | 1 | 1993 | 110 | 0.030 |
Why?
|
| Cross-Sectional Studies | 2 | 2011 | 25043 | 0.030 |
Why?
|
| Gastrointestinal Agents | 1 | 1998 | 494 | 0.030 |
Why?
|
| Aortic Valve | 1 | 1983 | 1922 | 0.030 |
Why?
|
| Coronary Occlusion | 1 | 2016 | 304 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2016 | 1005 | 0.030 |
Why?
|
| Neovascularization, Physiologic | 1 | 2000 | 1351 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 1997 | 2031 | 0.030 |
Why?
|
| Ventricular Pressure | 1 | 1993 | 199 | 0.030 |
Why?
|
| New England | 1 | 2016 | 1022 | 0.030 |
Why?
|
| Serum Sickness | 1 | 1992 | 28 | 0.030 |
Why?
|
| Antibodies, Viral | 2 | 2002 | 3176 | 0.030 |
Why?
|
| Haemophilus influenzae | 2 | 1990 | 171 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2000 | 2187 | 0.030 |
Why?
|
| Actins | 1 | 2000 | 2121 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 2 | 2000 | 6171 | 0.030 |
Why?
|
| Vasodilator Agents | 3 | 2002 | 977 | 0.030 |
Why?
|
| Disease Outbreaks | 1 | 2002 | 1772 | 0.030 |
Why?
|
| Mutagenesis, Site-Directed | 2 | 2007 | 1723 | 0.030 |
Why?
|
| Enterotoxins | 1 | 1993 | 368 | 0.030 |
Why?
|
| Abscess | 1 | 1996 | 607 | 0.030 |
Why?
|
| Pulmonary Valve Insufficiency | 1 | 1993 | 151 | 0.030 |
Why?
|
| Tomography | 1 | 1994 | 390 | 0.030 |
Why?
|
| Physical Exertion | 1 | 1994 | 695 | 0.030 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 1992 | 188 | 0.020 |
Why?
|
| Cholesterol | 1 | 2000 | 2917 | 0.020 |
Why?
|
| Enzyme Inhibitors | 4 | 2004 | 3798 | 0.020 |
Why?
|
| Hepatomegaly | 1 | 2010 | 85 | 0.020 |
Why?
|
| Thrombolytic Therapy | 1 | 2000 | 2161 | 0.020 |
Why?
|
| Hexosaminidases | 1 | 1990 | 54 | 0.020 |
Why?
|
| Paclitaxel | 1 | 1998 | 1708 | 0.020 |
Why?
|
| Acetylglucosaminidase | 1 | 1990 | 70 | 0.020 |
Why?
|
| Aortic Valve Stenosis | 1 | 1983 | 1965 | 0.020 |
Why?
|
| Opportunistic Infections | 1 | 1993 | 389 | 0.020 |
Why?
|
| Catheterization | 1 | 1996 | 1470 | 0.020 |
Why?
|
| Pyelonephritis | 1 | 1990 | 75 | 0.020 |
Why?
|
| Heart Arrest | 1 | 2000 | 1470 | 0.020 |
Why?
|
| Rabbits | 3 | 2002 | 4894 | 0.020 |
Why?
|
| Cystitis | 1 | 1990 | 93 | 0.020 |
Why?
|
| Hemolysis | 1 | 1992 | 420 | 0.020 |
Why?
|
| Membrane Proteins | 2 | 2000 | 7880 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2001 | 10943 | 0.020 |
Why?
|
| Prostheses and Implants | 1 | 1997 | 1387 | 0.020 |
Why?
|
| Echocardiography, Stress | 1 | 2010 | 131 | 0.020 |
Why?
|
| Goals | 1 | 2015 | 706 | 0.020 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 1994 | 1107 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type II | 2 | 2002 | 534 | 0.020 |
Why?
|
| Hemodynamics | 2 | 1998 | 4199 | 0.020 |
Why?
|
| Residence Characteristics | 1 | 2019 | 2050 | 0.020 |
Why?
|
| Clinical Competence | 2 | 2015 | 4687 | 0.020 |
Why?
|
| Acetylcholine | 2 | 2002 | 621 | 0.020 |
Why?
|
| Exercise | 1 | 2005 | 5615 | 0.020 |
Why?
|
| Retreatment | 1 | 2010 | 610 | 0.020 |
Why?
|
| Membrane Glycoproteins | 1 | 2000 | 3768 | 0.020 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 1990 | 142 | 0.020 |
Why?
|
| Linear Models | 1 | 2019 | 5952 | 0.020 |
Why?
|
| Radiography | 3 | 1997 | 7023 | 0.020 |
Why?
|
| Echocardiography, Transesophageal | 1 | 1995 | 1133 | 0.020 |
Why?
|
| Blood Chemical Analysis | 1 | 2010 | 440 | 0.020 |
Why?
|
| Organizational Objectives | 1 | 2010 | 438 | 0.020 |
Why?
|
| Transduction, Genetic | 2 | 2002 | 913 | 0.020 |
Why?
|
| Incidence | 2 | 2017 | 20947 | 0.020 |
Why?
|
| Myocardial Contraction | 1 | 1993 | 1585 | 0.020 |
Why?
|
| Staphylococcal Infections | 2 | 1996 | 1400 | 0.020 |
Why?
|
| Pyrazoles | 1 | 1998 | 1972 | 0.020 |
Why?
|
| Animals, Newborn | 1 | 1993 | 2726 | 0.020 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2010 | 392 | 0.020 |
Why?
|
| Educational Measurement | 1 | 2015 | 1210 | 0.020 |
Why?
|
| Middle Aged | 6 | 2011 | 213383 | 0.020 |
Why?
|
| Myocardial Infarction | 3 | 2016 | 11727 | 0.020 |
Why?
|
| Mitral Valve Insufficiency | 1 | 1997 | 1422 | 0.020 |
Why?
|
| Tachycardia, Ventricular | 1 | 2016 | 1273 | 0.020 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2000 | 3068 | 0.020 |
Why?
|
| Dyslipidemias | 1 | 2015 | 849 | 0.020 |
Why?
|
| Waiting Lists | 1 | 2012 | 692 | 0.020 |
Why?
|
| Anti-Arrhythmia Agents | 2 | 1998 | 789 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2016 | 35421 | 0.020 |
Why?
|
| Drug Therapy, Combination | 3 | 2003 | 6489 | 0.020 |
Why?
|
| Clavulanic Acids | 1 | 1986 | 11 | 0.020 |
Why?
|
| Cefaclor | 1 | 1986 | 8 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 1995 | 8949 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2000 | 5097 | 0.020 |
Why?
|
| Apoptosis | 2 | 2001 | 9727 | 0.020 |
Why?
|
| Teaching | 1 | 2015 | 1174 | 0.020 |
Why?
|
| Cephalexin | 1 | 1986 | 37 | 0.020 |
Why?
|
| Case-Control Studies | 3 | 2013 | 21746 | 0.020 |
Why?
|
| Health Care Rationing | 1 | 2010 | 437 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2022 | 10481 | 0.020 |
Why?
|
| Pilot Projects | 2 | 2013 | 8324 | 0.020 |
Why?
|
| Structure-Activity Relationship | 2 | 2003 | 3129 | 0.020 |
Why?
|
| Vesico-Ureteral Reflux | 1 | 1990 | 427 | 0.020 |
Why?
|
| Office Visits | 1 | 2010 | 598 | 0.020 |
Why?
|
| Comorbidity | 2 | 2015 | 10388 | 0.020 |
Why?
|
| Respiratory Tract Infections | 1 | 1993 | 961 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 6538 | 0.020 |
Why?
|
| Amoxicillin | 1 | 1986 | 170 | 0.020 |
Why?
|
| Mice | 5 | 2022 | 81183 | 0.020 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2000 | 3255 | 0.020 |
Why?
|
| Hemorrhage | 1 | 2017 | 3461 | 0.020 |
Why?
|
| Cell Death | 2 | 2001 | 1706 | 0.020 |
Why?
|
| Aortic Coarctation | 1 | 1987 | 281 | 0.020 |
Why?
|
| Cost Savings | 1 | 2010 | 926 | 0.020 |
Why?
|
| Proteins | 1 | 2000 | 6103 | 0.020 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2010 | 554 | 0.020 |
Why?
|
| Forecasting | 1 | 1994 | 2951 | 0.020 |
Why?
|
| Echocardiography, Doppler | 2 | 1999 | 935 | 0.020 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2011 | 1442 | 0.020 |
Why?
|
| Drainage | 1 | 1990 | 1142 | 0.020 |
Why?
|
| Otitis Media | 1 | 1986 | 277 | 0.020 |
Why?
|
| Postoperative Complications | 3 | 1997 | 15295 | 0.010 |
Why?
|
| Logistic Models | 2 | 2016 | 13408 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2017 | 4149 | 0.010 |
Why?
|
| Ionomycin | 1 | 2003 | 109 | 0.010 |
Why?
|
| Caveolin 2 | 1 | 2003 | 25 | 0.010 |
Why?
|
| Flow Cytometry | 3 | 2001 | 5974 | 0.010 |
Why?
|
| Tachycardia, Paroxysmal | 1 | 1983 | 31 | 0.010 |
Why?
|
| Thrombosis | 1 | 2017 | 2968 | 0.010 |
Why?
|
| Disease Progression | 2 | 2016 | 13284 | 0.010 |
Why?
|
| Glioma | 1 | 1998 | 3401 | 0.010 |
Why?
|
| Heart Transplantation | 1 | 2016 | 3110 | 0.010 |
Why?
|
| Massachusetts | 1 | 2016 | 8663 | 0.010 |
Why?
|
| Binding Sites | 2 | 2003 | 6114 | 0.010 |
Why?
|
| Methoxamine | 1 | 2002 | 45 | 0.010 |
Why?
|
| Adrenergic alpha-1 Receptor Agonists | 1 | 2002 | 19 | 0.010 |
Why?
|
| Casein Kinase II | 1 | 2003 | 128 | 0.010 |
Why?
|
| Angioplasty, Balloon | 1 | 1987 | 653 | 0.010 |
Why?
|
| omega-N-Methylarginine | 1 | 2002 | 111 | 0.010 |
Why?
|
| Health Services Research | 1 | 2010 | 1836 | 0.010 |
Why?
|
| Streptococcus pyogenes | 2 | 1995 | 289 | 0.010 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2003 | 821 | 0.010 |
Why?
|
| Superoxides | 1 | 2003 | 387 | 0.010 |
Why?
|
| Extracellular Space | 1 | 1984 | 594 | 0.010 |
Why?
|
| Treatment Outcome | 5 | 2010 | 63114 | 0.010 |
Why?
|
| Digoxin | 1 | 1983 | 250 | 0.010 |
Why?
|
| Caliciviridae Infections | 1 | 2002 | 29 | 0.010 |
Why?
|
| Odds Ratio | 1 | 1994 | 9849 | 0.010 |
Why?
|
| Mesenteric Artery, Superior | 1 | 2002 | 101 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 12354 | 0.010 |
Why?
|
| Curriculum | 1 | 2015 | 3605 | 0.010 |
Why?
|
| Culture Techniques | 1 | 2002 | 554 | 0.010 |
Why?
|
| Immune Sera | 1 | 2002 | 641 | 0.010 |
Why?
|
| Ligation | 1 | 2002 | 453 | 0.010 |
Why?
|
| Pulmonary Edema | 1 | 1984 | 414 | 0.010 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2002 | 464 | 0.010 |
Why?
|
| Mutation | 3 | 2002 | 29786 | 0.010 |
Why?
|
| Pulmonary Veins | 1 | 1987 | 761 | 0.010 |
Why?
|
| Chromones | 1 | 2000 | 154 | 0.010 |
Why?
|
| Lymphatic Diseases | 1 | 1982 | 324 | 0.010 |
Why?
|
| Androstadienes | 1 | 2002 | 346 | 0.010 |
Why?
|
| NADH Dehydrogenase | 1 | 2000 | 41 | 0.010 |
Why?
|
| Social Adjustment | 1 | 2003 | 631 | 0.010 |
Why?
|
| Egtazic Acid | 1 | 2000 | 173 | 0.010 |
Why?
|
| Pandemics | 1 | 2020 | 8388 | 0.010 |
Why?
|
| Tunica Media | 1 | 2000 | 113 | 0.010 |
Why?
|
| Bacterial Proteins | 1 | 1993 | 3848 | 0.010 |
Why?
|
| Guinea Pigs | 1 | 2002 | 1386 | 0.010 |
Why?
|
| Pulmonary Circulation | 2 | 1998 | 739 | 0.010 |
Why?
|
| Hydrolysis | 1 | 2001 | 682 | 0.010 |
Why?
|
| Serum Albumin, Bovine | 1 | 2000 | 324 | 0.010 |
Why?
|
| Angiopoietin-1 | 1 | 2000 | 114 | 0.010 |
Why?
|
| Gastroenteritis | 1 | 2002 | 245 | 0.010 |
Why?
|
| Protein Binding | 2 | 2003 | 9386 | 0.010 |
Why?
|
| Vasomotor System | 1 | 2000 | 209 | 0.010 |
Why?
|
| Chronic Disease | 1 | 1994 | 9146 | 0.010 |
Why?
|
| Portal Vein | 1 | 2002 | 437 | 0.010 |
Why?
|
| Macromolecular Substances | 1 | 2002 | 1454 | 0.010 |
Why?
|
| Static Electricity | 1 | 2000 | 267 | 0.010 |
Why?
|
| Nitroglycerin | 1 | 2000 | 325 | 0.010 |
Why?
|
| NADP | 1 | 2000 | 226 | 0.010 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2000 | 215 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2004 | 1730 | 0.010 |
Why?
|
| Heart Ventricles | 2 | 1996 | 3821 | 0.010 |
Why?
|
| Electrons | 1 | 2000 | 268 | 0.010 |
Why?
|
| Coronary Artery Disease | 1 | 2018 | 6487 | 0.010 |
Why?
|
| Cisapride | 1 | 1998 | 22 | 0.010 |
Why?
|
| Aspartic Acid | 1 | 2001 | 576 | 0.010 |
Why?
|
| Pressure | 1 | 2002 | 1203 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 3 | 2002 | 21827 | 0.010 |
Why?
|
| Vasoconstrictor Agents | 1 | 2002 | 642 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2003 | 2839 | 0.010 |
Why?
|
| Hindlimb | 1 | 2000 | 504 | 0.010 |
Why?
|
| Prevalence | 1 | 2015 | 15226 | 0.010 |
Why?
|
| Ventilation-Perfusion Ratio | 1 | 1998 | 116 | 0.010 |
Why?
|
| Dimerization | 1 | 2000 | 893 | 0.010 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2001 | 697 | 0.010 |
Why?
|
| Genes, Dominant | 1 | 2000 | 880 | 0.010 |
Why?
|
| Antigens, Viral | 1 | 2002 | 1035 | 0.010 |
Why?
|
| Carotid Arteries | 1 | 2002 | 952 | 0.010 |
Why?
|
| Embryo, Mammalian | 1 | 2003 | 1701 | 0.010 |
Why?
|
| Morpholines | 1 | 2000 | 571 | 0.010 |
Why?
|
| Atrioventricular Node | 1 | 1998 | 182 | 0.010 |
Why?
|
| Adenosine Triphosphate | 1 | 2003 | 2025 | 0.010 |
Why?
|
| Brain Neoplasms | 1 | 1998 | 8863 | 0.010 |
Why?
|
| Amino Acid Sequence | 2 | 2003 | 13815 | 0.010 |
Why?
|
| Prospective Studies | 3 | 2012 | 53288 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 2000 | 1525 | 0.010 |
Why?
|
| Emergencies | 1 | 1983 | 1170 | 0.010 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 1997 | 364 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 2001 | 1791 | 0.010 |
Why?
|
| Methylmethacrylate | 1 | 1995 | 44 | 0.010 |
Why?
|
| Age of Onset | 1 | 2003 | 3271 | 0.010 |
Why?
|
| Methylmethacrylates | 1 | 1995 | 72 | 0.010 |
Why?
|
| Femoral Artery | 1 | 2000 | 845 | 0.010 |
Why?
|
| Acute Disease | 3 | 1993 | 7149 | 0.010 |
Why?
|
| Glutamic Acid | 1 | 2001 | 1169 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 1993 | 10180 | 0.010 |
Why?
|
| Angiocardiography | 2 | 1987 | 162 | 0.010 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 1984 | 1265 | 0.010 |
Why?
|
| Gene Transfer Techniques | 1 | 2000 | 1224 | 0.010 |
Why?
|
| Cytoskeleton | 1 | 2000 | 1185 | 0.010 |
Why?
|
| Aorta | 1 | 2003 | 2061 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2000 | 1959 | 0.010 |
Why?
|
| Imidazoles | 1 | 2001 | 1206 | 0.010 |
Why?
|
| Single-Blind Method | 1 | 1998 | 1590 | 0.010 |
Why?
|
| Fluoroscopy | 1 | 1998 | 924 | 0.010 |
Why?
|
| Exotoxins | 1 | 1993 | 119 | 0.010 |
Why?
|
| Reoperation | 1 | 1983 | 4201 | 0.010 |
Why?
|
| Physicians | 1 | 2012 | 4567 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2016 | 20129 | 0.010 |
Why?
|
| Protein Conformation | 1 | 2001 | 4011 | 0.010 |
Why?
|
| Estradiol | 1 | 2000 | 2020 | 0.010 |
Why?
|
| Premedication | 1 | 1993 | 258 | 0.010 |
Why?
|
| Postoperative Period | 1 | 1997 | 1842 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2002 | 3420 | 0.010 |
Why?
|
| Adaptation, Psychological | 1 | 2003 | 2576 | 0.010 |
Why?
|
| Drug Resistance | 1 | 1998 | 1609 | 0.010 |
Why?
|
| Streptococcus agalactiae | 1 | 1993 | 375 | 0.010 |
Why?
|
| Transducers | 1 | 1993 | 252 | 0.010 |
Why?
|
| Gastroesophageal Reflux | 1 | 1998 | 782 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2002 | 8301 | 0.010 |
Why?
|
| Cell Survival | 1 | 2001 | 5882 | 0.010 |
Why?
|
| Drug Administration Schedule | 2 | 1991 | 4933 | 0.010 |
Why?
|
| Emergency Service, Hospital | 1 | 2010 | 7659 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2002 | 4803 | 0.010 |
Why?
|
| Stroke Volume | 1 | 1983 | 5007 | 0.010 |
Why?
|
| Bronchopulmonary Dysplasia | 1 | 1993 | 306 | 0.010 |
Why?
|
| ABO Blood-Group System | 1 | 1992 | 367 | 0.010 |
Why?
|
| Immunoglobulin A | 1 | 1993 | 992 | 0.010 |
Why?
|
| Hospitalization | 1 | 2009 | 10262 | 0.010 |
Why?
|
| Pyridines | 1 | 2001 | 2825 | 0.010 |
Why?
|
| Streptococcal Infections | 1 | 1993 | 638 | 0.010 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 1993 | 805 | 0.010 |
Why?
|
| Cryopreservation | 1 | 1993 | 670 | 0.010 |
Why?
|
| Exercise Tolerance | 1 | 1993 | 770 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1993 | 2505 | 0.010 |
Why?
|
| Anticonvulsants | 1 | 1998 | 1916 | 0.000 |
Why?
|
| Infant, Newborn, Diseases | 1 | 1993 | 582 | 0.000 |
Why?
|
| Heart Valve Diseases | 1 | 1996 | 1073 | 0.000 |
Why?
|
| Aged | 3 | 1998 | 163280 | 0.000 |
Why?
|
| Kidney | 1 | 2003 | 7186 | 0.000 |
Why?
|
| Neoplasm Proteins | 1 | 2000 | 3703 | 0.000 |
Why?
|
| Neisseria | 1 | 1986 | 12 | 0.000 |
Why?
|
| Clavulanic Acid | 1 | 1986 | 19 | 0.000 |
Why?
|
| Dandy-Walker Syndrome | 1 | 1987 | 43 | 0.000 |
Why?
|
| Mice, Knockout | 1 | 2002 | 14557 | 0.000 |
Why?
|
| Clinical Trials as Topic | 2 | 1996 | 7913 | 0.000 |
Why?
|
| Prednisone | 1 | 1990 | 1574 | 0.000 |
Why?
|
| Otitis Media with Effusion | 1 | 1986 | 114 | 0.000 |
Why?
|
| Models, Biological | 1 | 2002 | 9583 | 0.000 |
Why?
|
| Transplantation, Homologous | 1 | 1993 | 4776 | 0.000 |
Why?
|
| Lymphocyte Activation | 1 | 1995 | 5524 | 0.000 |
Why?
|
| Partial Pressure | 1 | 1984 | 254 | 0.000 |
Why?
|
| Artifacts | 1 | 1993 | 1904 | 0.000 |
Why?
|
| Aortic Rupture | 1 | 1987 | 310 | 0.000 |
Why?
|
| Blood Transfusion | 1 | 1990 | 1301 | 0.000 |
Why?
|
| Survival Rate | 1 | 1998 | 12788 | 0.000 |
Why?
|
| Autoimmune Diseases | 1 | 1995 | 2133 | 0.000 |
Why?
|
| Necrosis | 1 | 1987 | 1643 | 0.000 |
Why?
|
| Aortic Aneurysm | 1 | 1987 | 643 | 0.000 |
Why?
|
| Heart Aneurysm | 1 | 1982 | 120 | 0.000 |
Why?
|
| Random Allocation | 1 | 1986 | 2429 | 0.000 |
Why?
|
| Base Sequence | 1 | 1993 | 12797 | 0.000 |
Why?
|
| Streptococcus pneumoniae | 1 | 1986 | 714 | 0.000 |
Why?
|
| Aorta, Thoracic | 1 | 1987 | 1082 | 0.000 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 1993 | 4386 | 0.000 |
Why?
|
| Immunoglobulin G | 1 | 1991 | 4560 | 0.000 |
Why?
|
| Heart Failure | 1 | 1983 | 10900 | 0.000 |
Why?
|
| DNA | 1 | 1993 | 7301 | 0.000 |
Why?
|
| Transcription, Genetic | 1 | 1993 | 7722 | 0.000 |
Why?
|
| Abnormalities, Multiple | 1 | 1984 | 1416 | 0.000 |
Why?
|
| Angiography | 1 | 1982 | 1639 | 0.000 |
Why?
|
| Cohort Studies | 1 | 1998 | 40561 | 0.000 |
Why?
|
| Risk | 1 | 1982 | 9687 | 0.000 |
Why?
|
| Blood Pressure | 1 | 1984 | 8554 | 0.000 |
Why?
|